Stockreport

XBiotech Move To Out-Licence Next Generation Antibody Brings In Substantial Cash For Pipeline Expansion [Seeking Alpha]

XBiotech Inc.  (XBIT) 
Last xbiotech inc. earnings: 8/9 03:01 pm Check Earnings Report
US:NASDAQ Investor Relations: xbiotech.com/about/investors.html
PDF Summary XBiotech enters into out-licensing agreement for $1.35 billion whereby it will provide its drug Bermekimab for use by Johnson & Johnson for dermatological indica [Read more]